A novel radiolabeled indole derivative as solid tumor imaging agent: in silico and preclinical pharmacological study

Biologically active indole derivative was synthesized and screened for its cytotoxicity against breast cancer cell line (MCF-7) with the IC50 equals 17.5 µg/mL. Docking study showed its high binding affinity to the COX-2 enzyme. It’s radiolabeling with 99mTc and showed high radiochemical yield (92.10 ± 0.57%) and in vitro stability in serum up to 10 h. Biodistribution studies of a novel 99mTc-NSIC complex in tumor-bearing mice showed high T/NT ratio (6.17 ± 0.08 at 30 min. post-injection), suggesting this complex could be used as a solid tumor imaging agent.